Seer, Inc. (SEER) is a life sciences company that develops the Proteograph product suite, an integrated platform for deep, unbiased proteomic analysis. Analyst coverage of this small-cap is limited. Current tracked targets — from sources such as MarketBeat, MarketWatch, and Investing.com — center almost entirely on $4.00. Canaccord Genuity analyst Kyle Mikson initiated coverage with a Buy rating and a $4.00 target in May 2026 and reiterated that view in July 2026, while TD Cowen's Daniel Brennan has also maintained a Buy rating.
Because the handful of valid targets all sit at $4.00, the calculated mean is $4.00, and the practical low-to-high range is effectively flat. This is important context: the target is not a broad, diversified consensus but a small cluster of bullish views. Readers should treat $4.00 as a single, thin-coverage figure rather than a robust Wall Street average.
Seer's stock last traded near $1.96, within a 52-week range of roughly $1.55 to $2.39. The company's market capitalization is about $108 million, while it held roughly $153 million in cash and investments as of its most recent quarter — meaning the business's enterprise value is slightly negative and the shares trade below book value (a price-to-book ratio near 0.5).
From about $1.96, reaching $4.00 would require a gain of approximately 104%, which qualifies as a very large move. Such a re-rating would almost certainly depend on a material acceleration in revenue, evidence that the Proteograph platform is converting research adoption into recurring commercial demand, and a decisive shift in how investors value an unprofitable but cash-rich company.
Several factors could underpin upward momentum. Seer's balance sheet is a notable cushion: cash and investments far exceed its market value, limiting near-term dilution risk. The company has surpassed 100 peer-reviewed customer publications, and researchers at Nanyang Technological University have presented early findings from the large-scale PRECISE-SG100K proteomics study, lending scientific credibility to the platform. A co-marketing partnership with Thermo Fisher Scientific extends commercial reach, and analysts framing a $4.00 target have cited expectations for higher revenue growth and improved profitability over time.
The obstacles are equally real. Seer remains deeply unprofitable, with trailing-twelve-month revenue around $14 million against a net loss of roughly $68 million, and negative EPS (earnings per share) of about -$1.22. Demand is tied closely to academic, government, and biopharmaceutical research budgets, which can be sensitive to funding uncertainty. The announced departure of President and CFO David Horn in October 2026 introduces leadership transition risk. Finally, with analyst coverage thin and targets concentrated at a single level, there is little independent corroboration to support the bullish case.
Seer shares are trading just above their 200-day simple moving average (around $1.92) but below the 50-day moving average (near $2.02), a configuration that suggests a long-term base but near-term hesitation. The 52-week high near $2.39 acts as the first meaningful resistance level and a psychological hurdle before any test of higher prices. The $1.55 area marks the recent support level and a key downside reference. A sustained move above $2.39 would be an early sign of shifting market structure, though it would still leave a long path to $4.00.
Analyst price targets typically reflect a roughly 12-month research horizon, though with such thin coverage the implied timeframe should be treated with caution. The most immediate catalyst is Seer's third-quarter 2026 earnings report, scheduled for November 10, 2026. Investors should watch revenue trajectory, cash burn, gross margin, commentary on the Proteograph pipeline and partnerships, and any updates on the CFO transition. Any additions or changes to analyst coverage would also be significant, given how concentrated current targets are.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly covered stock like SEER, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual scanning alone. Traders interested in a more systematic approach can explore these signals to complement their own research.
Can Seer, Inc. stock reach $4? The $4.00 central target — drawn from a small cluster of current analyst views, not a broad consensus — implies a roughly 104% advance from a price near $1.96, a very large move by any standard. The case rests on Seer's unusual cash-to-market-value profile, a sub-book-value valuation, and early scientific and commercial validation of its proteomics platform. Against that stand persistent losses, modest revenue, research-budget sensitivity, and leadership change. With analyst targets concentrated at a single level and no meaningful spread, investors have limited independent guidance. The outcome will hinge most on sustained revenue acceleration and evidence that the platform's adoption translates into durable commercial traction, beginning with the November earnings report.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SEER has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SEER jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To SEER | 1D Price Change % | ||
|---|---|---|---|---|
| SEER | 100% | -2.03% | ||
| AXON - SEER | 56% Loosely correlated | +1.05% | ||
| ARRY - SEER | 47% Loosely correlated | -1.25% | ||
| VCYT - SEER | 35% Loosely correlated | +0.56% | ||
| RNA - SEER | 35% Loosely correlated | -1.83% | ||
| DNA - SEER | 34% Loosely correlated | +0.30% | ||
More | ||||